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ABSTRACT 
The use of pronucleotides to circumvent the well-known drawbacks of nucleotide 
analogues has played a significant role in the area of antiviral and anticancer drug 
delivery. Several motifs have been designed to mask the negative charges on the 
phosphorus moiety of either nucleoside monophosphates or nucleoside phosphonates, 
in order to increase their hydrophobicity and allow entry of the compound into the cell.  
Among them the bis-amidate analogues, having two identical amino acids as masking 
groups through a P–N bond, represent a more recent approach for the delivery of 
nucleotide analogues, endowed with antiviral or anticancer activity. Two synthetic 
strategies are commonly used for preparing phosphorodiamidates of nucleosides. Both 
techniques will be here described using two nucleosides as model substrates: Stavudine 
and Acadesine. A third strategy for preparing diamidates of nucleoside phosphonates 
will be reported using Adefovir as model substrate.  
Keywords: Phosphorodiamidates, nucleoside, phosphonate, antiviral, bis-amidate. 
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INTRODUCTION 
In order to achieve oral bioavailability and intracellular delivery of nucleoside 
monophosphates and phosphonates of antiviral and anticancer interest, numerous 
prodrug strategies have been explored. Using various approaches the ionizable 
phosphate group can be masked by derivatization, thus generating pronucleotides with 
increased lipophilicity. (Aziza et al. 2005; Wagner et al. 2000; Schultz et al. 2003; Pertusati 
et al. 2012; Peterson et al. 2009; Li et al. 2007; Krise et al. 1996; Hecker et al. 2008; He et al. 
2007)  The rationale behind the design of such agents is to achieve temporary blockage 
of the free phosphoric or phosphonic functional group until their systemic absorption 
and delivery, allowing the release of free drug only once at the target. Among all the 
different classes of prodrugs the ProTide approach developed by McGuigan group 
(Mcguigan et al. 1993) including both aryloxy mono-amidate (Serpi et al. 2013) and bis-
amidate derivatives has been proved to boost the activity of parent nucleosides by 
increasing the formation rate of nucleoside triphosphates, by improving intracellular 
transport and/or bypassing the rate limiting monophosphorylation step (Derudas et al. 
2009; Mcguigan et al. 2010; McGuigan et al. 2011; Mehellou et al 2009; Slusarczyk et al. 
2014; Toti et al. 2014; Serpi et al. 2012; McGuigan et al. 2014). Several leading 
pharmaceutical companies have already applied the pioneering aryloxy mono-amidate 
technology for anti-viral and anticancer treatments.  
More recently the phosphorodiamidate technology applied to several anticancer and 
antiviral nucleoside analogues was also reported as a new successful approach for the 
delivery of monophosphates inside the cell (McGuigan et al. 2013; McGuigan et al., 
2011). In this approach two amino acid esters are introduced on the monophosphate 
moiety in order to mask the negative charges. Bis-amidates derivatives offer two 
distinct advantages when compared to the aryloxy mono-amidate analogues. Due to 
their symmetric structure no phosphorus chirality arises, and exclusively non-toxic 
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promoieties are released during the prodrug bioactivation. This novel prodrug 
approach has been validated both in vitro and in vivo and some compounds are already 
under consideration for clinical studies. Among them, GS-9191 active against papilloma 
viruses is now under clinical development (Phase I clinical trials) by Gilead science as a 
topical prodrug for the treatment of HPV lesions (Wolfgang et al. 2009). 
Herein we present a strategy for obtaining the phosphorodiamidate prodrugs. The 
method involve the phosphorylation of nucleoside by phosphorus oxychloride (POCl3) 
in tetrahydrofuran (THF) in the presence of triethylamine, followed by reaction with an 
excess of the appropriate amino acid ester as p-toluene sulfonate (p-TSA) salt in the 
presence of triethylamine (McGuigan et al. 2013; McGuigan et al. 2011]. The model 
compounds employed was 2'-3'-didehydro-2'-3'-dideoxythymidine (d4T, stavudine), a 
nucleoside analogue approved for the treatment of HIV infection. Additionally, we 
report the application of a more recent synthetic methodology to prepare 
phosphonodiamidate derivatives, starting from free phosphonic acid of {[2-(6-amino-
9H-purin-9-yl)ethoxy]methyl}phosphonic acid (PMEA, adefovir) via bis-trimethylsilyl 
ester intermediates (Basic Protocol 2) (Jansa et al. 2011; Pertusati et al.; 2014). Adefovir is 
a potent ANP endowed with antiviral activity and currently its bis (pivaloy-loxymethyl) 
ester (bis-(POM)-PMEA; Hepsera®) is on the market for the treatment of HBV 
infections (Starrett et al. 1994). 
CAUTION: Carry out all operations involving organic solvents and reagents in a well-
ventilated fume hood. Wear appropriate protective clothing and eye/face protection. 
NOTE: All glassware should be oven dried, and all reactions should be performed 
under anhydrous conditions. For the synthesis of the amino acid ester not commercially 
available please see see Support Protocol unit 15.5.8 (Serpi et al. 2013). 
 
BASIC PROTOCOL 1 
4 
 
Preparation of bis-amidate prodrugs of 2′,3′-didehydro-2′,3′-dideoxythymidine 
This protocol describes the synthesis of bis-amidate prodrugs of d4T nucleoside. In this 
strategy, the unprotected nucleoside (1 equiv.) dissolved in THF is treated with 
phosphorus oxychloride (1 equiv.) in the presence of triethylamine (1 equiv.) to 
generate a phosphorodichloridate intermediate 2 (31P-NMR signal at ~7-8 ppm reference 
to H3PO4), which is not isolated. Then, an excess of the appropriate amino acid ester as 
p-toluene sulfonate (p-TSA) salt (5 eq.) and triethylamine (5 eq.) are added at -78 oC, 
leading after 18 to 20 hours at room temperature to the desired phosphorodiamidate 
3a,b (31P-NMR signals at P ~ 12-14 ppm) (Figure 1). In the case of 1 only the 5’-OH is 
present. In case of nucleoside having more reactive hydroxyl group, either alternate 
Protocol 2 or selective protection procedures are recommended. 
 
Figure 1. Synthesis of d4T phosphordiamidates (3a,b). 
 
Materials 
Anhydrous dichloromethane (CH2Cl2) (Sigma-Aldrich) 
Anhydrous tetrahydrofuran (THF) (Sigma-Aldrich) 
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Triethylamine (Et3N) (Sigma-Aldrich) 
Phosphoryl chloride (POCl3) (Sigma-Aldrich) 
(L)-Alanine cyclohexyl ester p-toluensulfonate (see Support Protocol unit 15.5.8)  
(L)-Alanine 2,2-dimethylpropylester p-toluensulfonate (see Support Protocol unit 15.5.8) 
2'-3'-Didehydro-2'-3'-dideoxythymidine (d4T, Stavudine, Carbosynth) 
Dichloromethane (Fluka)   
Methanol (Fluka) 
Dry nitrogen (N2) or Argon (Ar)  
Anhydrous Na2SO4 (Sigma-Aldrich)  
Silica gel (35-70, 60A; Fluka/Fisher)  
Sand (Sigma-Aldrich) 
50-, 100-, and 500-mL round-bottom flasks 
Magnetic stirrer plate 
Dry ice/Acetone bath  
Analytical TLC plate (aluminum-backed TLC plates, precoated with silica gel 60 
F254, 0.2 mm; Merck Kieselgel) 
250-mL separating funnel  
Glass funnel  
Filter paper  
Rotary evaporator equipped with vacuum pump (BUCHI) 
Vacuum desiccator 
Chromatography columns: 2.5 x 30–cm  
UV light source 
MeOH-d4 (Goss) 
Acetonitrile HPLC grade (FISHER) 
Water HPLC grade (FISHER) 
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Varian Pursuit XRs 5 C18, 150 x 4.6 mm  
Bruker Daltonics microTof-LC, (electron spray ionization) in positive mode 
Bruker Avance 500 NMR spectrometer 
Thermo SCIENTIFIC, SPECTRA SYSTEM P4000, detector SPECTRA SYSTEM UV2000 
 
1.  In a 25 mL round bottom flask, prepare a solution of 0.5 g 1 (2.23 mmol) 
in anhydrous THF (5 mL) under an Argon atmosphere.  
2.  Add 0.31 mL anhydrous Et3N (2.23 mmol) under an argon atmosphere.  
3.  Stir at room temperature for 30 min and then add 0.21 mL POCl3 (2.23 
mmol) dropwise at -78 °C.  
4.  Stir the reaction mixture at -78 °C for 30 min and then allow to reach 
room temperature in 1h.  
5.  After 5 h, monitor the reaction by 31P-NMR using a CDCl3 as an internal 
standard and to achieve lock. Leave the reaction longer if POCl3 (singlet 
at ~4 ppm) is still present along with the desired phosphorylated 
nucleoside 2 (singlet at ~6 ppm). 
5. Once completion of the reaction is confirmed by 31P NMR, dilute the 
solution with anhydrous CH2Cl2 (10 mL) and add 3.82 g  (L)-alanine 
cyclohexylester p-toluensulfonate salt (11.15 mmol) for 3a and 3.69 g 
(L)-alanine 2,2-dimethylpropylester  p-toluensulfonate salt (11.15 mmol) 
for 3b. 
6.  Cool down the solution to -78 °C and then add dropwise anhydrous 1.5 
mL Et3N (11.15 mmol).                                       
7.  Stir the reaction mixture at room temperature for 12h.  
8.  Add H2O (4 mL) and extract the aqueous phase with CH2Cl2 (2 x 5 mL).  
9.  Wash the organic phase with brine (4 mL), dry over anhydrous MgSO4. 
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Filter and evaporate to dryness.  
10.  Prepare silica gel (45 g) slurry for flash chromatography in CH2Cl2. Pour 
the slurry into a 2.5 x 30 cm chromatography column. 
11. Dissolve the crude product in the minimum amount of CH2Cl2 and 
carefully place the solution on top of the column. Layer 1.5 cm of sand 
on top of the column. 
12.  Elute the first 250 mL with 98:2 (v/v) CH2Cl2/MeOH, change to 97:3 (v/v) 
CH2Cl2/MeOH (250mL) and then to 95:5 (v/v/) CH2Cl2/MeOH to elute 
the desired product. 
13.  Monitor the fractions by TLC using 9:1 (V/V) CH2Cl2/MeOH (Rf = 0.30) 
as elution solvent and visualize by UV light. Combine the fractions 
containing pure products and evaporate to dryness using a rotary 
evaporator under reduced pressure to obtain 3a,b. 
14. Dry the pure compounds under vacuum (20 mbar) for 12 h. 
15. Characterize the compounds by 1H, 13C, 31P NMR and HRMS. 
16. Check the purity of the compound by reverse phase HPLC 
Phosphoramidate derivatives of d4T are stable for several years when stored at -20C under 
argon atmosphere. 
31P NMR spectra documented below were obtained with proton decoupling. 
d4T-5′-O-bis-(cyclohexyloxy-L-alaninyl)-phosphate (3a). yield of white solid 0.66 g (46%). 1H 
NMR (500 MHz, MeOH-d4) δH 7.44 (s, 1H, H-6), 6.99 (m, 1H, H-1’), 6.45 (dd, J = 6.0, 1.2 Hz, 
1H, H-3’), 5.99 (dd, J = 6.0, 1.2 Hz, 1H, H-2’), 5.02 (bs, 1H, H-4’), 4.78-4.74 (m, 2H, 2 x 
OCH), 4.21-4.14 (m, 2H, H-5’), 3.90-3.84 (m, 2H, CHCH3), 1.92 (s, 3H, CH3), 1.90-1.80 (m, 
4H, cHx), 1.80-1.70 (m, 4H, cHx), 1.63-1.55 (m, 2H, cHx), 1.54-1.29 (m, 10H, cHx), 1.36 (d J = 
7.0 Hz, 3H, CHCH3), 1.32 (d, J = 7.0 Hz, 3H, CHCH3).  13C NMR (125 MHz, MeOH-d4), δC = 
175.05 (d, 3JC-P = 5.0 Hz, C=O), 174.89 (d, 3JC-P = 5.0 Hz, C=O), 166.37 (C-4), 152.81 (C-2), 
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137.97 (C-6), 134.98 (C-3’), 127.95 (C-2’), 112.14 (C-5), 91.21 (C-1’), 86.57 (d, 3JC-P = 8.75 Hz, 
C-4’), 74.88, 74.86 (2 x OCH), 67.44 (d, 2JC-P = 5.0 Hz, C-5’), 51.22 (d, 2JC-P = 1.12 Hz, CHCH3), 
50.99 (d, 2JC-P = 1.12 Hz, CHCH3), 32.57, 32.56, 32.50, 32.48 (CH2 cHx), 26.48, 24.75, 24.72, 
24.68 (CH2 cHx), 21.15 (d, 3JC-P = 5.0 Hz, CHCH3), 20.95 (d, 3JC-P = 5.0 Hz, CHCH3), 12.73 
(CH3).31P NMR (202 MHz, MeOH-d4) δP 12.58. (ES+) m/z: 633.25 (M+Na+, 100%). Reverse 
HPLC, eluting with H2O/CH3CN from 90:10 to 0:100 in 30 min, Flow = 1 mL/min, UV 
Detector = 254 nm, tR = 18.48 min. 
 
d4T-5’-O-bis-(2,2-dimethylpropoxy-L-alaninyl)-phosphate (3b). Yield of white solid 0.15 g 
(12%). 1H NMR (500 MHz, MeOH-d4) δH 7.44 (s, 1H, H-6), 7.01-6.90 (m, 1H, H-1’), 6.46-
6.40 (m, 1H, H-3’), 6.00-5.90 (m, 1H, H-2’), 5.03 (bs, 1H, H-4’), 4.21-4.14 (m, 2H, H-5’), 3.98-
3.92 (m, 2H, 2 x CHCH3), 3.91, 3.89, 3.78, 3.76 (2 x AB JAB = 10.05 Hz, 4H, 2 x 
OCH2C(CH3)3), 1.92 (s, 3H, CH3), 1.40 (d, J = 7.0 Hz, 6H, 2 x CHCH3), 0.976 (s, 9H, 
OCH2C(CH3)3), 0.972 (s, 9H, OCH2C(CH3)3).13C NMR (125 MHz, MeOH-d4), δC = 175.64 (d, 
3JC-P = 5.0 Hz, C=O), 175.47 (d, 3JC-P = 5.0 Hz, C=O), 166.41 (C-4), 152.85 (C-2), 137.97 (C-6), 
134.98 (C-3’), 127.93 (C-2’), 112.14 (C-5), 91.22 (C-1’), 86.57 (d, 3JC-P = 8.75 Hz, C-4’), 75.45 (2 
x OCH2C(CH3)3), 67.54 (d, 2JC-P = 5.0 Hz, C-5’), 51.19 (d, 2JC-P = 1.12 Hz, CHCH3), 50.82 (d, 2JC-
P = 1.12 Hz, CHCH3), 32.36 (2 x OCH2C(CH3)3), 26.87, 26.60 (2 x OCH2C(CH3)3), 21.19 (d, 3JC-
P = 5.0 Hz, CHCH3), 21.01 (d, 3JC-P = 5.0 Hz, CHCH3), 12.71 (CH3). 31P NMR (202 MHz, 
MeOH-d4) δP  13.73. MS (ES+) m/z: 609.27 (M+Na+, 100%) Reverse-phase HPLC, eluting with 
H2O/CH3CN from 90:10 to 0:100 i 254 nm, tR = 17.80 min. 
 
BASIC PROTOCOL 2 
 
Synthesis of bis-amidate prodrugs of {[2-(6-amino-9H-purin-9-
yl)ethoxy]methyl}phosphonic acid  
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This protocol describes the preparation of bis-amidate produgs of Adefovir (Jansa et al. 
2011). According to this methodology, overnight reaction of Adefovir (1eq) with 
trimethylsilyl bromide (5 eq) in acetonitrile (10 mL/mmol) affords the intermediate 
bis(trimethylsilyl)-phosphonate ester 5, which once isolated without purification is 
reacted with an excess of the desired amino acid ester (4 eq) in pyridine (10mL/mmol)  
in the presence of triethylamine (4 eq) aldrithiol-2 (6 eq) and triphenylphosphine (6 eq) 
(Figure 2). This two-steps reaction gives the corresponding (L)-Alanine diamidate 
prodrug 6 in 25% overall yields, after purification by column chromatography. The 
reaction can be monitored by 31P NMR spectroscopy analysis to ensure the completion 
of each step. 
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Figure 2. Synthesis of Adefovir phosphorodiamidates 6 
Materials 
Adefovir (Hubei Maxsource chemical Co., Ltd, Wuhan, China) 
(L)-Alanine 2,2-dimethylpropylester p-toluensulfonate (see Support Protocol unit 15.5.8) 
Trimethylsilyl bromide (Sigma-Aldrich)  
Anhydrous pyridine (Sigma-Aldrich)  
Anhydrous acetonitrile (Sigma-Aldrich)  
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Aldrithiol-2 (Sigma-Aldrich)  
Triphenylphosphine (Sigma-Aldrich)  
Dry nitrogen (N2) or Argon (Ar)  
Methanol (Fluka) 
Toluene (Fluka) 
Hexane (Fluka) 
Ethyl acetate (Fluka)  
Dichloromethane (Fluka) 
Anhydrous Na2SO4 (Sigma-Aldrich)  
Silica gel (35-70μ, 60A; Fluka/Fisher)  
Sand (Sigma-Aldrich) 
50-, 100-, and 500-mL round-bottom flasks (Fisher) 
Magnetic stirrer plate 
Oil bath  
Analytical TLC plate (aluminum-backed TLC plates, precoated with silica gel 60 
F254, 0.2 mm; Merck Kieselgel) 
 250-mL separating funnel 
Glass funnel  
Filter paper  
Rotary evaporator equipped with vacuum pump (BUCHI) 
Sintered glass funnel 
Vacuum desiccator 
Chromatography columns: 5 x 20–cm and 4.5 x 23–cm  
UV light source 
MeOH-d4 (Goss) 
Acetonitrile HPLC grade (FISHER) 
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Water HPLC grade (FISHER) 
Varian Pursuit XRs 5 C18, 150 x 4.6 mm  
Bruker Daltonics microTof-LC, (electron spray ionization) in positive mode 
Bruker Avance 500 NMR spectrometer 
ThermoSCIENTIFIC, SPECTRA SYSTEM P4000, detector SPECTRA SYSTEM UV2000 
 
1. In a 25 mL round bottomed flask, prepare a solution of 0.2 g Adefovir 
(0.73 mmol) in 7.3 mL of dry acetonitrile under Argon atmosphere. 
2. Add 0.481 mL TMSBr (3.65 mmol) under argon and stir the resulting 
mixture at rt overnight.  
3. Remove the solvents under reduced pressure without any contact with air. 
4. Dissolve the residue in 1.46 mL anhydrous Et3N and 5.8 mL pyridine. 
5. Add 1.35 g (L)-alanine 2,2-dimethylpropylester p-toluensulfonate salt (2.92 
mmmol) and heat the reaction at 50 °C to obtain a homogeneous solution. 
6. In a separated flask, dissolve 0.964 g Aldrithiol-2 (4.38 mmol) and 1.15 g 
triphenylphosphine (4.38 mmol) in 7.3 mL anhydrous pyridine. 
7. Add this solution to the reaction mixture under argon. 
8. Stir the resulting mixture (green solution) at 50 °C for 3-5 h.  
9. Cool down the solution at rt and evaporate the solvents on the rotary 
evaporator. 
10. Add a mixture of methanol, water, toluene and hexane 1:1:1:1 (10/10/10/10 
mL) to the residue and transfer the mixture into a separatory funnel. 
11. Remove the upper layer (Hex/toluene) and wash the lower phase with a 
mixture of toluene and hexane 1:1 (v/v) three times.  
12. Remove the upper layer and extract the lower layer (MeOH/H2O) three 
times with ethyl acetate (3 x 20 mL). 
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13. Combine the ethyl acetate phase, dry over MgSO4, filter and evaporate. 
14. Prepare silica gel (45 g) slurry for flash chromatography in CH2Cl2. Pour 
the slurry into a 2.5 x 30 cm chromatography column. 
15. Dissolve the crude product in the minimum amount of CH2Cl2 and 
carefully place the solution on top of the column. Layer 1.5 cm of sand on 
top of the column. 
16.  Elute the first 250 mL with 98:2 (v/v) CH2Cl2/MeOH, change to 97:3 (v/v) 
CH2Cl2/MeOH (250mL) and then to 95:5 (v/v/) CH2Cl2/MeOH to elute the 
desired product. 
17. Monitor the fractions by TLC using 9:1 (V/V) CH2Cl2/MeOH (Rf = 0.34) as 
elution solvent and visualize by UV light. Combine the fractions 
containing pure products and evaporate to dryness using a rotary 
evaporator under reduced pressure to obtain 6. 
18. Dry the pure compound under vacuum for 12 h 
19. Characterize the compounds by 1H, 13C, 31P NMR and HRMS. 
20. Check the purity of the compound by reverse phase HPLC. 
 
9-[2-(Phenyloxy-(2,2-dimethylpropoxy-L-alaninyl)-Phosphonomethoxy)ethyl]adenine. (6) Yield 
of an off-white solid 100 mg (25%) 1H NMR (500 MHz, MeOH-d4):  8.21 (s, 1H, H-2), 8.20 (s, 
1H, H-2), 8.18 (s, 1H, H-8), 8.16 (s, 1H, H-8), 7.30-7.22 (m, 4H, Ph), 7.14 (t, J = 8.2 Hz, 2H, 
Ph), 7.12 (t, J = 8.1 Hz, 2H, Ph), 7.06 (d, J = 8.1 Hz, 2H, Ph), 4.43 (m, 4H, N-CH2), 4.07 – 3.85 
(m, 10H, CH2-P, N-CH, OCH2CH2N), 3.81, 3.71 (AB, JAB = 10.0 Hz, 2H, OCH2C(CH3)3), 3.80, 
3.70 (AB, JAB = 10.0 Hz, 2H, OCH2C(CH3)3), 1.29 (d, J = 7.3 Hz, 3H, CH3-aa), 1.28 (d, J = 7.3 
Hz, 3H, CH3-aa), 0.95 (s, 9H, C(CH3)3), 0.94 (s, 9H, C(CH3)3) ppm. 13C-NMR (125 MHz, 
MeOH-d4):  175.33 (d, 3JC-P = 4.0 Hz, C=O), 175.09 (d, 3JC-P = 4.0 Hz, C=O), 157.32,157.30 (C-
6), 153.76, 153.72 (CH-2), 151.50 (d, 2JC-P = 9.0 Hz, C-ipso OPh), 151.41 (d, 2JC-P = 9.0 Hz, C-
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ipso OPh), 150.75, 150.73 (C-4), 143.41, 143.38 (CH-8), 130.76, 130.74, 126.17, 126.11 (Ph), 
121.94 (d, 3JC-P = 4.5 Hz, Ph), 121.76 (d, 3JC-P = 4.5 Hz, Ph), 119.99, 119.95 (C-5), 75.40, 75.37 
(OCH2C(CH3)3), 72.37 (d, 3JC-P = 11.9 Hz, OCH2CH2N), 72.26 (d, 3JC-P =12.9 Hz, OCH2CH2N), 
67.51 (d, 1JC-P = 155.3 Hz, CH2-P), 67.48 (d, 1JC-P = 155.3 Hz, CH2-P), 51.02, 50.92 (N-CH), 
44.69, 44.65 (N-CH2), 32.34 (C(CH3)3), 26.77, 26.74, (C(CH3)3), 21.26 (d, 3JC-P = 5.3 Hz, CH3-
aa), 20.74 (d, 3JC-P = 5.3 Hz, CH3-aa) ppm. 31P NMR (202 MHz, MeOH-d4):  23.71, 22.68 ppm. 
MS (ES+) m/z: 513.49 [M+Na+]. Reverse-phase HPLC, eluting with H2O/MeOH from 90/100 to 
0/100 in 30 min, Flow = 1 mL/min,  = 263 nm, tR = 15.74 min. 
 
COMMENTARY 
Background Information 
Numerous studies have shown that aryloxy phosphoramidate nucleosides are able to 
enhance, in vitro and in vivo, the activity of parent nucleosides endowed with a variety 
of biological activities. As result of these studies several leading pharmaceutical 
companies have successfully taken advantage of this technology. Gilead, has just 
launched on the market its anti-HCV ProTide, Sofosbuvir (PSI-7977) and at the same 
time it has exploited this technology to create an advanced anti-HIV drug (GS 7340), 
which is now in Phase III clinical trial. Nucana Biomed has taken to trial a gemcitabine 
ProTide, (NUC-1031, Acelarin) for treating patients with advanced solid tumours. These 
prodrugs are usually prepared as 1:1 diastereomeric mixtures due to the formation of a 
new chiral center at the phosphorus atom. Most of these prodrugs that have entered 
into the clinic to date have been progressed as diastereoisomeric mixtures at the 
phosphate center. One exception is Sofosbuvir, which, due to a 18-fold difference in 
activity between the two diastereoisomers, has been launched in the market as a single 
isomer resolved entity (Sp) at considerable difficulty and expense by Gilead. Up to now 
the phosphoramidate prodrugs could not be easily prepared in the form of single 
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diastereoisomers because of lack of control of the stereochemistry at the phosphorus 
centre during the synthesis.  For this reason more recently the notion of an achiral 
phosphate prodrug motif such as a symmetrical bis-amidate was re-explored.  
Diamide prodrugs to mask a nucleoside monophosphate were indeed reported for the 
first time almost 20 years ago. Interestingly after the first appearence, no further reports 
ensued seeking to explore and optimize the utility of this class of nucleoside 
monophosphate prodrugs. Despite these disappointing earlier results and the slow 
evolution of this class, the result of these new investigations indicates the bis-amidate as 
a promising new phosphate prodrug motif for drug discovery. 
 
In particular, researchers at Gilead Sciences were able to show the utility of diamide 
prodrugs applied to ANPs, a class of broad spectrum antiviral agents active against 
DNA viruses and retroviruses. A study seeking inhibitors of orthopoxvirus replication 
demonstrated that GS-8357, PMEA bis-amidate containing L -alanine n-butyl ester was 
as effective as the bis-POM prodrug in cellular antiviral assays, indicating effective 
cellular permeation and intracellular prodrug cleavage [Keith et al. 2003]. Later, they 
also reported the GS-9219, a PMEG (phospho-nomethoxyethylguanine) prodrug to 
selectively deliver the active agent to lymphoid cells [Reiser et al. 2008]. Similarly, 
several ANP phosphonodiamidates containing alkyl (L)-alanine were reported to 
exhibit potent antiviral activities, being GS-9191,bis(isobutyl-(L)-
phenylalaninyl)phosphonodi-amidate-PME-N6 (cyclopropyl) DAP the most active of 
the series against Human papilloma Viruse (HPV) and currently in Phase I clinical trials 
as a topical prodrug for the treatment of HPV lesions.  
 
Critical Parameters and Troubleshooting 
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The synthetic procedures described in this article, are intended for use only by persons 
with prior training in experimental organic chemistry and thus with knowledge of the 
common chemical laboratory techniques such as solvent evaporation, extraction, TLC, 
column chromatography and HPLC. Characterization of the products demands 
knowledge of monodimensional (1H, 13C, 31P) and bidimensional (COSY, HSQC and 
HMBC) NMR experiments as well as of ESI mass spectroscopy.  
General laboratory safety is also of primary concern when hazardous materials are 
involved. Strict adherence to the reported procedures is therefore highly recommended. 
Anhydrous conditions are strictly required for both procedures reported. The solvents 
need to be dry and the nucleosides and the amino acids need to be dried under vacuum 
for 24h prior their use. It is recommended to use POCl3 and TMSBr freshly distilled. 
For basic protocol 1 the amino acid ester, if soluble, can be dissolved in 
dichloromethane and added via syringe to the reaction mixture. For diamidate prodrugs 
having a low log P value, the aqueous work up must be avoided in order to minimize 
the lost of compound in the water phase.  
In basic protocol 2 in step 12 depending on the compounds dichloromethane could be 
more efficient as extraction solvent. For basic protocol 2 all the extraction sequence are 
necessary and highly recommended in order to obtain pure product; they indeed help 
the purification process.  
Anticipated Results 
The protocols described here for exemplary bis-amidates prodrugs and three parent 
nucleosides can be applied to other nucleoside analogues and  a  wide  range  of amino 
acid esters.  The yields of the desired products that can be expected vary from 12% to 
46%.   
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Time Considerations 
The synthesis of the phosphorodiamidate prodrugs can be accomplished in 2 days 
when following either basic protocol 1. Preparation of the phosphonodiamidate 
prodrugs according to basic protocol 2 requires 2 to 3 days. The amino acid ester can be 
prepared in 1 day. 
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